iMBIORAY Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $28.7M

  • Investors
  • 15

iMBIORAY General Information

Description

Developer of innovative drugs intended for the treatment of tumors and immune diseases. The company offers research and clinical development programs focused on off-the-shelf natural killer cell therapies, with a drug focus on technology in non-genetically modified CAR-NK (Chimeric antigen receptor-NK) and Bispecific monoclonal antibody, providing enabling oncology and immunology clinicians, research hospitals, and biopharma cancer patients with advanced and targeted treatment.

Contact Information

Website
www.imbioray.com
Formerly Known As
Hangzhou Yingbairui Biomedical Technology Co., Ltd.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 101, Building 32, Number 365 Changjiang Road, Changhe Street
  • Binjiang District
  • Hangzhou, Zhejiang 900000
  • China
+86 188
Primary Industry
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Room 101, Building 32, Number 365 Changjiang Road, Changhe Street
  • Binjiang District
  • Hangzhou, Zhejiang 900000
  • China
+86 188

iMBIORAY Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iMBIORAY Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B) 05-Feb-2026 $28.7M Completed Generating Revenue
7. Later Stage VC 02-Jul-2025 Completed Generating Revenue
6. Later Stage VC (Series A1) 22-Jan-2025 Completed Generating Revenue
5. Secondary Transaction - Private 17-Nov-2022 Completed Generating Revenue
4. Secondary Transaction - Private 23-May-2022 Completed Generating Revenue
3. Later Stage VC (Series A) 22-Feb-2022 Completed Generating Revenue
2. Later Stage VC 11-Mar-2021 $12.4M $12.4M Completed Generating Revenue
1. Secondary Transaction - Private 09-Jul-2020 Completed Generating Revenue
To view iMBIORAY’s complete valuation and funding history, request access »

iMBIORAY Patents

  • 23

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 20

    Pending

  • Expiring in next 12 mo

iMBIORAY Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026208837-A1 Antibody against liver-intestine cadherin and use thereof Pending 03-Apr-2025
WO-2026194875-A1 Use of nk cells in treatment of systemic lupus erythematosus Pending 21-Mar-2025
WO-2026098676-A1 Use of nk cells in treating vitiligo and psoriasis Pending 11-Nov-2024
WO-2026098676-A9 Use of nk cells in treating vitiligo and psoriasis Pending 11-Nov-2024
WO-2025247296-A1 Bispecific antibody against human c-met and human egfr, and use thereof Pending 30-May-2024 C07K16/2863
To view iMBIORAY’s complete patent history, request access »

iMBIORAY Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Deep Intelligent Pharma VC-Backed Company Minority
Hangzhou Hi-Tech Financial Investment Group Venture Capital Minority
Zhejiang Zheda Qizhen Venture Capital University Minority
Hangzhou 5050 Plan Government Minority
Hangzhou Tailong Venture Capital Partnership Growth/Expansion Minority
You’re viewing 5 of 15 investors. Get the full list »

Ready to get started?

Request a free trial

iMBIORAY FAQs

  • When was iMBIORAY founded?

    iMBIORAY was founded in 2014.

  • Where is iMBIORAY headquartered?

    iMBIORAY is headquartered in Hangzhou, China.

  • What industry is iMBIORAY in?

    iMBIORAY’s primary industry is Drug Discovery.

  • Is iMBIORAY a private or public company?

    iMBIORAY is a Private company.

  • What is iMBIORAY’s current revenue?

    The current revenue for iMBIORAY is .

  • How much funding has iMBIORAY raised over time?

    iMBIORAY has raised $90.9M.

  • Who are iMBIORAY’s investors?

    Deep Intelligent Pharma, Hangzhou Hi-Tech Financial Investment Group, Zhejiang Zheda Qizhen Venture Capital, Hangzhou 5050 Plan, and Hangzhou Tailong Venture Capital Partnership are 5 of 15 investors who have invested in iMBIORAY.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process